Recombinant Insulin-Like Growth Factor 1 Dimers: Receptor Binding Affinities and Activation Abilities

[1]  M. Lepšík,et al.  Targeting the insulin receptor with hormone and peptide dimers , 2022, Journal of peptide science : an official publication of the European Peptide Society.

[2]  C. Kahn,et al.  Interaction of a viral insulin-like peptide with the IGF-1 receptor produces a natural antagonist , 2022, Nature Communications.

[3]  X. Bai,et al.  Synergistic activation of the insulin receptor via two distinct sites , 2022, Nature Structural & Molecular Biology.

[4]  M. Erion,et al.  Discovery of Insulin Receptor Partial Agonists MK-5160 and MK-1092 as Novel Basal Insulins with Potential to Improve Therapeutic Index. , 2022, Journal of medicinal chemistry.

[5]  Ingmar B. Schäfer,et al.  Symmetric and Asymmetric Receptor Conformation Continuum induced by a Novel Insulin , 2022, Nature Chemical Biology.

[6]  P. Nissen,et al.  Structural investigations of full-length insulin receptor dynamics and signalling. , 2022, Journal of molecular biology.

[7]  C. Kahn,et al.  A viral insulin-like peptide is a natural competitive antagonist of the human IGF-1 receptor , 2021, Molecular metabolism.

[8]  D. Leroith,et al.  The insulin-like growth factors: ligands, binding proteins and receptors. , 2021, Molecular metabolism.

[9]  M. Lawrence.  Understanding insulin and its receptor from their three-dimensional structures , 2021, Molecular metabolism.

[10]  M. Mann,et al.  Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains , 2021, Proceedings of the National Academy of Sciences.

[11]  Margaret S. Wu,et al.  Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists , 2021, Nature communications.

[12]  J. Wit,et al.  Disorders of IGFs and IGF-1R signaling pathways , 2020, Molecular and Cellular Endocrinology.

[13]  D. Yee,et al.  Advances in insulin-like growth factor biology and -directed cancer therapeutics. , 2020, Advances in cancer research.

[14]  X. Bai,et al.  Structural basis of the activation of type 1 insulin-like growth factor receptor , 2019, Nature Communications.

[15]  P. Hobza,et al.  Mutations at hypothetical binding site 2 in insulin and insulin-like growth factors 1 and 2 result in receptor- and hormone-specific responses , 2019, The Journal of Biological Chemistry.

[16]  X. Bai,et al.  Activation mechanism of the insulin receptor revealed by cryo-EM structure of the fully liganded receptor–ligand complex , 2019, eLife.

[17]  Ingmar B. Schäfer,et al.  Cryo-EM structure of the complete and ligand-saturated insulin receptor ectodomain , 2019, bioRxiv.

[18]  C. Müller,et al.  The signalling conformation of the insulin receptor ectodomain , 2018, Nature Communications.

[19]  Frank Wien,et al.  BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra , 2018, Nucleic Acids Res..

[20]  J. Menting,et al.  How ligand binds to the type 1 insulin-like growth factor receptor , 2018, Nature Communications.

[21]  J. Mayer,et al.  Controlled intramolecular antagonism as a regulator of insulin receptor maximal activity , 2018, Peptides.

[22]  A. Brzozowski,et al.  Insulin-like Growth Factor 1 Analogs Clicked in the C Domain: Chemical Synthesis and Biological Activities. , 2017, Journal of medicinal chemistry.

[23]  T. Walz,et al.  Visualization of ligand-induced transmembrane signaling in the full-length human insulin receptor , 2017, bioRxiv.

[24]  M. Lawrence,et al.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View , 2017, Endocrine reviews.

[25]  Zdeněk Tošner,et al.  Probing Receptor Specificity by Sampling the Conformational Space of the Insulin-like Growth Factor II C-domain* , 2016, The Journal of Biological Chemistry.

[26]  Brian J. Smith,et al.  Higher-Resolution Structure of the Human Insulin Receptor Ectodomain: Multi-Modal Inclusion of the Insert Domain. , 2016, Structure.

[27]  R. Cardiff,et al.  An Integrin Binding-defective Mutant of Insulin-like Growth Factor-1 (R36E/R37E IGF1) Acts as a Dominant-negative Antagonist of the IGF1 Receptor (IGF1R) and Suppresses Tumorigenesis but Still Binds to IGF1R* , 2013, The Journal of Biological Chemistry.

[28]  R. Baserga.  The decline and fall of the IGF‐I receptor , 2013, Journal of cellular physiology.

[29]  P. Arvan,et al.  Contribution of Residue B5 to the Folding and Function of Insulin and IGF-I , 2009, The Journal of Biological Chemistry.

[30]  D. Clemmons.  Role of IGF-I in skeletal muscle mass maintenance , 2009, Trends in Endocrinology & Metabolism.

[31]  V. Kiselyov,et al.  Harmonic oscillator model of the insulin and IGF1 receptors' allosteric binding and activation , 2009, Molecular systems biology.

[32]  M. Weiss,et al.  Comparative properties of insulin-like growth factor 1 (IGF-1) and [Gly7D-Ala]IGF-1 prepared by total chemical synthesis. , 2008, Angewandte Chemie.

[33]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[34]  M. Lawrence,et al.  Structure of the insulin receptor ectodomain reveals a folded-over conformation , 2006, Nature.

[35]  E. Barton,et al.  Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. , 2006, Journal of applied physiology.

[36]  G. Booker,et al.  Molecular interactions of the IGF system. , 2005, Cytokine & growth factor reviews.

[37]  B. Honig,et al.  A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.

[38]  M. White.  Insulin Signaling in Health and Disease , 2003, Science.

[39]  D. Roith.  The Insulin-Like Growth Factor System , 2003, Experimental Diabesity Research.

[40]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[41]  A. Musarò,et al.  Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice , 2002, The Journal of cell biology.

[42]  G. Lynch,et al.  IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice , 2001, Neuromuscular Disorders.

[43]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[44]  B. Ursø,et al.  Modelling of the disulphide-swapped isomer of human insulin-like growth factor-1: implications for receptor binding. , 1999, Protein engineering.

[45]  P. D. Meyts,et al.  The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling , 1994, Diabetologia.

[46]  C. Christoffersen,et al.  Negative cooperativity in the insulin-like growth factor-I receptor and a chimeric IGF-I/insulin receptor. , 1994, Endocrinology.

[47]  J. Miller,et al.  Oxidative refolding of insulin-like growth factor 1 yields two products of similar thermodynamic stability: a bifurcating protein-folding pathway. , 1993, Biochemistry.

[48]  S. Hober,et al.  Disulfide exchange folding of insulin-like growth factor I. , 1992, Biochemistry.

[49]  H. Joost,et al.  Antagonistic effects of a covalently dimerized insulin derivative on insulin receptors in 3T3-L1 adipocytes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Willey,et al.  Evidence concerning the mechanism of insulin-receptor interaction and the structure of the insulin receptor from biological properties of covalently linked insulin dimers. , 1983, The Biochemical journal.

[51]  D. Neville,et al.  Insulin interactions with its receptors: experimental evidence for negative cooperativity. , 1973, Biochemical and biophysical research communications.

[52]  D E Koshland,et al.  Negative cooperativity in regulatory enzymes. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Matsuba,et al.  [Insulin receptor]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[54]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[55]  D. Brandenburg,et al.  Preparation and properties of covalently linked insulin dimers. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.